SynthesisJournal of neuro-oncology2025
Systematic review of disease-specific quality of life in patients with sporadic vestibular schwannoma.
Synthesis in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo systematically review the existent data on disease-specific quality of life (QOL) measures for sporadic vestibular schwannoma (VS), with a specific focus on comparing QOL outcomes among observation, radiosurgery, and microsurgery.
methodsSystematic review.
resultsA systematic review identified 751 unique publications on QOL in VS, with a total of 39 articles reporting disease-specific measures of QOL. Of these, 26 articles evaluated QOL of VS patients after management, including 14 that compared QOL metrics among observation, radiosurgery, and microsurgery. When comparing these three primary treatment modalities for VS, nine of the 14 articles did not demonstrate clinically significant differences in QOL scores among treatment types. There were no consistent trends among the publications to help guide selection of treatment modality based on QOL scores.
conclusionWhile disease-specific tools exist for quantifying QOL in VS, to date, no consistent, clinically significant differences in QOL have been reported among management strategies for patients with sporadic VS.
Indexed as
Identifiers
41441907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.